Next Article in Journal
Design and Optimization of a Nanoparticulate Pore Former as a Multifunctional Coating Excipient for pH Transition-Independent Controlled Release of Weakly Basic Drugs for Oral Drug Delivery
Previous Article in Journal
Preparation and Characterization of Ibuprofen Containing Nano-Embedded-Microparticles for Pulmonary Delivery
Previous Article in Special Issue
Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 2
10.3390/pharmaceutics15020546
Review Report
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Nanomedicine for Combination Urologic Cancer Immunotherapy

Pharmaceutics 2023, 15(2), 546; https://doi.org/10.3390/pharmaceutics15020546
by Yun Tian 1,†, Zhenzhu Liu 2,†, Jianbo Wang 1, Linan Li 3, Fuli Wang 4, Zheng Zhu 5,* and Xuejian Wang 1,*
Reviewer 2:
Raheleh Roudi
Reviewer 3: Anonymous
Pharmaceutics 2023, 15(2), 546; https://doi.org/10.3390/pharmaceutics15020546
Submission received: 4 January 2023 / Revised: 31 January 2023 / Accepted: 2 February 2023 / Published: 6 February 2023
(This article belongs to the Special Issue Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of Solid Tumors)

Round 1

Reviewer 1 Report

Review for the article “Nanomedicine for combination urologic cancer immunotherapy”

The paper entitled “Nanomedicine for combination urologic cancer immunotherapy” described the principles of cancer immunotherapy in urology. The authors also wanted to emphasis the role of nanomendicine in immunotherapy in urologic cancer.

The objectives and the rationale of the study are clearly stated. The interpretation of results and study conclusions supported by the data. The authors clearly emphasized the strengths of their study.

The results presented in the study are very promising for clinicians.

The presentation is clear. The writing style is clear. 

Author Response

Please see the attachment.

Author Response File: Author Response.doc

Reviewer 2 Report

1) The effects of chemotherapy and immunotherapy has been investigated on a wide range of tumors including urological cancers. It is strongly suggested that the authors add a new part regarding the combination of chemotherapy and immunotherapy in urological cancers using the related and recent publications

2) The similarities and differences in treatment of urological cancers with immunotherapy agents should compare with other common cancers treated with immunotherapy such as lung cancer, melanoma and so on using the relevant publications for example Alfredo Tartarone, et al - 2019 and Fausto Petrelli, et al - 2021 and Monireh Mohsenzadegan, et al - 2020 in lung cancer and so on 

3) Adding a image about the content can help researcher to understand the article better. 

Author Response

Please see the attachment.

Author Response File: Author Response.doc

Reviewer 3 Report

The authors provide a comprehensive review summarising current efforts to develop a targeted immuntherapy/immunodiagnosis of urological cancers via delivery with nanoparticles.

As a minor amendment, It is of interest to know whether cationic lipids - known to be cytotoxic - are involved in any of the presented nanoparticle developments. If available, such information should be added.

Author Response

Please see the attachment.

Author Response File: Author Response.doc

Round 2

Reviewer 2 Report

Accept in present form. 

Back to TopTop